These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23685443)

  • 1. What is the place of pre-exposure prophylaxis in HIV prevention?
    De Man J; Colebunders R; Florence E; Laga M; Kenyon C
    AIDS Rev; 2013; 15(2):102-11. PubMed ID: 23685443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of pre-exposure prophylaxis for HIV: a review.
    Schackman BR; Eggman AA
    Curr Opin HIV AIDS; 2012 Nov; 7(6):587-92. PubMed ID: 23076124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV treatment as prevention: population effect vs. individual protection?
    Ippolito G; Rezza G
    Ann Ig; 2013; 25(2):93-7. PubMed ID: 23471446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral drugs for pre-exposure prophylaxis of HIV infection.
    Fernández-Montero JV; Barreiro P; Del Romero J; Soriano V
    AIDS Rev; 2012; 14(1):54-61. PubMed ID: 22297504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Untangling the cost-effectiveness knot: who is oral antiretroviral HIV pre-exposure prophylaxis really for?
    Hankins CA
    Expert Rev Pharmacoecon Outcomes Res; 2014 Apr; 14(2):167-70. PubMed ID: 24552641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of adherence to oral pre-exposure prophylaxis for HIV - how can we improve uptake and adherence?
    Sidebottom D; Ekström AM; Strömdahl S
    BMC Infect Dis; 2018 Nov; 18(1):581. PubMed ID: 30445925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postexposure prophylaxis after sexual exposure to HIV.
    Roland ME
    Curr Opin Infect Dis; 2007 Feb; 20(1):39-46. PubMed ID: 17197880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review.
    Hankins CA; Dybul MR
    Curr Opin HIV AIDS; 2013 Jan; 8(1):50-8. PubMed ID: 23201856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.
    Desai K; Sansom SL; Ackers ML; Stewart SR; Hall HI; Hu DJ; Sanders R; Scotton CR; Soorapanth S; Boily MC; Garnett GP; McElroy PD
    AIDS; 2008 Sep; 22(14):1829-39. PubMed ID: 18753932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-exposure prophylaxis for human immunodeficiency virus: the past, present, and future.
    Castel AD; Magnus M; Greenberg AE
    Infect Dis Clin North Am; 2014 Dec; 28(4):563-83. PubMed ID: 25455314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbicides-emerging essential pillars of comprehensive HIV/AIDS prevention.
    Gaym A
    Ethiop Med J; 2006 Oct; 44(4):405-15. PubMed ID: 17370443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparing for PrEP.
    Lacor P
    Eur J Contracept Reprod Health Care; 2012 Dec; 17(6):482-6. PubMed ID: 23113873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV.
    Pinkerton SD; Holtgrave DR; Bloom FR
    AIDS; 1998 Jun; 12(9):1067-78. PubMed ID: 9662204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.
    Pinkerton SD; Martin JN; Roland ME; Katz MH; Coates TJ; Kahn JO
    Arch Intern Med; 2004 Jan; 164(1):46-54. PubMed ID: 14718321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preexposure prophylaxis for the prevention of HIV transmission to women.
    Aaron E; Cohan D
    AIDS; 2013 Jan; 27(1):F1-5. PubMed ID: 22914582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using a network-based approach and targeted maximum likelihood estimation to evaluate the effect of adding pre-exposure prophylaxis to an ongoing test-and-treat trial.
    Balzer L; Staples P; Onnela JP; DeGruttola V
    Clin Trials; 2017 Apr; 14(2):201-210. PubMed ID: 28124579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV pre-exposure prophylaxis.
    Morin SF; Yamey G; Rutherford GW
    BMJ; 2012 Aug; 345():e5412. PubMed ID: 22890030
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of HIV nonoccupational post-exposure prophylaxis in Australia.
    Guinot D; Ho MT; Poynten IM; McAllister J; Pierce A; Pell C; Grulich AE
    HIV Med; 2009 Apr; 10(4):199-208. PubMed ID: 19207598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic preexposure prophylaxis for human immunodeficiency virus infection.
    Romanelli F; Murphy B
    Pharmacotherapy; 2010 Oct; 30(10):1021-30. PubMed ID: 20874040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.